Academic partner
of Lymphoma
Clinical Research

Biology platform: LYSA-BIO

In the coming years, the improvement of lymphoma treatment will largely benefit from the tremendous knowledge accumulated in recent years in immunopathology.

biologieIn addition to conventional cytotoxic drugs, new therapeutic strategies will include treatments targeting tumor cells and cellular microenvironment involved in lymphoma genesis or in treatment sensitivity.

LYSA decided to reorganize the biological aspects of clinical trials by creating LYSA-BIO, gathering multiple experts on specific platforms, with logistical and technical support from LYSARC staff.

Issues of residual disease, custom blood assays, suitable immunological monitoring, as well as specific genetic analyses can now be performed with standardized protocols and validated techniques.